ADMA BIOLOGICS, INC. (ADMA) Insider Trading & SEC Filings
Last SEC filing
ADMA BIOLOGICS, INC. (ADMA) has filed 5 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-29. Insiders disclosed 3 open-market purchases totaling $251K. 2 Form 8-K material event filings were reported by ADMA in the last 90 days. InsiderAlpha tracks every ADMA SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. trades under the ticker ADMA. InsiderAlpha tracks 39 primary SEC Form 4 filings from 10 reporting insiders for ADMA since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| SEC CIK | 0001368514 |
90-Day SEC Filing Activity
| Insider purchases (90d) | 3 ($251K) |
|---|---|
| Form 4 filings (90d) | 5 |
| Form 8-K filings (90d) | 2 |
| Latest Form 4 filing | 2026-07-29 |
Recent ADMA Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | F - Tax withholding / forfeiture | 3.2K | $8.37 | $27K | SEC | |
| Terry Kohler | CFO and Treasurer | A - Grant or award | 85.1K | $0.00 | - | SEC | |
| Jerrold B. Grossman | Insider | P - Open-market purchase | 6.4K | $7.91 | $51K | SEC | |
| Jerrold B. Grossman | Insider | P - Open-market purchase | 12.5K | $8.01 | $100K | SEC | |
| Jerrold B. Grossman | Insider | P - Open-market purchase | 12.5K | $8.01 | $100K | SEC | |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | F - Tax withholding / forfeiture | 20.4K | $9.11 | $185K | SEC | |
| Lawrence P. Guiheen | Insider | G - Bona-fide gift | 30.0K | $0.00 | - | SEC | |
| Lawrence P. Guiheen | Insider | G - Bona-fide gift | 30.0K | $0.00 | - | SEC | |
| Adam S. Grossman | President and CEO | M - Option exercise [10b5-1] | 15.0K | $5.40 | $81K | SEC | |
| Adam S. Grossman | President and CEO | S - Open-market sale [10b5-1] | 15.0K | $15.16 | $227K | SEC | |
| Adam S. Grossman | President and CEO | S - Open-market sale [10b5-1] | 6.0K | $15.16 | $91K | SEC | |
| Lawrence P. Guiheen | Insider | M - Option exercise | 30.0K | $3.66 | $110K | SEC | |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | S - Open-market sale | 10.1K | $15.63 | $158K | SEC | |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | M - Option exercise | 2.5K | $5.00 | $12K | SEC | |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | M - Option exercise | 2.6K | $2.83 | $7K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for ADMA BIOLOGICS, INC. (ADMA). Updated in real time as new filings are submitted to the SEC.
Most-Active ADMA Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Jerrold B. Grossman | 3 | $251K |
| Terry Kohler | 2 | - |
| Kaitlin M. Kestenberg-Messina | 1 | $27K |
Recent ADMA Form 8-K Material Events
- - Item 5.07 [SEC]
- - Item 2.02, 9.01 [SEC]
- - Item 8.01, 9.01 [SEC]
- - Item 7.01, 9.01 · Other · neutral [SEC]
ADMA Biologics issued a press release on March 27, 2026, disclosed via Regulation FD. The specific content of the press release is not provided in the 8-K excerpt, making detailed assessment of the announcement's substance impossible. - - Item 7.01, 8.01, 9.01 · Financing · positive [SEC]
ADMA Biologics entered into a $125 million accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank on March 2, 2026, as part of its previously announced $500 million share repurchase program. The company will fund the repurchases using its existing $225 million revo
Recent Insider Filings
- - Kaitlin M. Kestenberg-Messina (COO and SVP, Compliance)
- - Terry Kohler (CFO and Treasurer)
- - Jerrold B. Grossman (Insider)
- - Jerrold B. Grossman (Insider)
- - Jerrold B. Grossman (Insider)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ADMA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
ADMA Insider Trading - FAQ
- What is the latest insider trade for ADMA?
- ADMA BIOLOGICS, INC. (ADMA) had 5 insider filings in the last 90 days, with the most recent on 2026-07-29. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying ADMA stock?
- 3 insider purchases of ADMA were filed in the last 90 days, totaling $251K.
- How many insiders are selling ADMA stock?
- 0 insider sales of ADMA were filed in the last 90 days.
- Where can I see ADMA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks ADMA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $AEMD AETHLON MEDICAL INC
- $AHCO AdaptHealth Corp.
- $AIM AIM ImmunoTech Inc.
- $AKTX Akari Therapeutics Plc
- $ALMS ALUMIS INC.
- $ANNX Annexon, Inc.
- $APGE Apogee Therapeutics, Inc.
- $APVO Aptevo Therapeutics Inc.
- $ARTL ARTELO BIOSCIENCES, INC.
- $ARTV Artiva Biotherapeutics, Inc.
Related Companies - Recent Insider Activity
- AMGEN INC (AMGN)
- NEUROCRINE BIOSCIENCES INC (NBIX)
- Twist Bioscience Corp (TWST)
- Kymera Therapeutics, Inc. (KYMR)
- EXELIXIS, INC. (EXEL)
- Moderna, Inc. (MRNA)
- BioCardia, Inc. (BCDA)
- RECURSION PHARMACEUTICALS, INC. (RXRX)
- Maze Therapeutics, Inc. (MAZE)
- MeiraGTx Holdings plc (MGTX)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live ADMA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.